touchIMMUNOLOGY were delighted to speak with Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) about the results from the phase 2B/3 study of filgotinib in patients with ulcerative colitis as well as the use of the Partial Mayo Clinical Score in measuring outcomes.
His presentation entitled ‘EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY’ was given at UEG Week Virtual, 3-5 Oct 2021.
- What are the advantages of the Partial Mayo Clinic Score (pMCS) as an outcome measure in clinical trials for ulcerative colitis? (0:17)
- What were the aims and design of the SELECTION study? (1:42)
- What were the findings in terms of pMCS? (3:07)
- What are the clinical implications of these findings, and where do you see filgotinib sitting in the treatment paradigm for UC? (3:46)
Disclsoures: Dr Marc Ferrante has received grants from Amgen, Biogen, Janssen, Pfizer and Takeda; personal fees from, Abbvie, Amgen, Biogen, Boehringer Ingelheim, Celltrion, Falk, Ferring, Janssen, Lamepro, Eli Lilly, Medtronic, MSD, Mylan, Pfizer, Sandoz, Takeda, Thermo Fisher and Truvion Healthcare and non-financial support from AbbVie, Amgen, Biogen, Boehringer-Ingelheim, Celltrion, Falk, Ferring, Janssen, Lamepro, Lilly, Medtronic, MSD, Mylan, Pfizer, Sandoz, Takeda, Thermo Fisher and Truvion Healthcare.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of UEG Week Virtual, 3-5 Oct 2021.
Share this Video
Related Videos In Digestive Disorders
UEG Young Talent Group – aims, key achievements and opportunities for early career gastroenterologists: Pilar Acedo
The UEG Young Talent Group (YTG) encourages young gastroenterologists to develop their careers through education, networking and training. We were delighted to catch up with UEG YTG Chair Dr. Pilar Acedo to discuss the training, education and professional opportunities available to young digestive healthcare specialists through UEG, the aims and key achievements of the UEG […]
Highlights from Digestive Disease Week 2023: Gil Y. Melmed
Digestive Disease Week took place between 6-9 May, in this touchIMMUNOLOGY interview, we caught up with our Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) around his personal highlights from this year’s conference including non-pivotal clinical trial data analysing established inflammatory bowel disease (IBD) therapies such as vedolizumab, data around the […]
Comparison study of upadacitinib and tofacitinib as induction treatment in ulcerative colitis: Gil Y. Melmed, DDW 2023
Upadacitinib and tofacitinib are both JAK inhibitors (JAKis) approved by the FDA for the treatment of ulcerative colitis. In this interview with Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) we discuss the aims, design and findings from his study presented at DDW 2023, comparing the efficacy and safety of these […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!